GOOD MORNING

What is R&D???

R&D MAKES A SIGNIFICANT CONTRIBUTION TO THE COMPETITIVE STRENGTH OF INDUSTRIES, LARGE AS WELL AS SMALL,IN NATIONAL AS WELLAS INTERNATIONAL MARKETS “INNOVATE OR PERISH” IS THE LAW OF THE LAND. NOW-A-DAYS BEING GREATEST IS NOT IMPORTANT, BUT ALL THE MORE IMPORTANT IS THAT OF BEING LATEST.

OBJECTIVES OF R&D

• QUALITY IMPROVEMENT• COST REDUCTION• OVERCOMING PROCESS PROBLEMS• CONSUMER DELIGHT OR MARKET NEEDS• EXPLOITING THE OPPORTUNITY IN THE

MARKET FOR A NEW PRODUCT• EXPANSION & DIVERSIFICATION

• PRODUCT INNOVATION

• PROCESS INNOVATION

• PRODUCT DEVELOPMENT

MANAGEMENT OF TECHNOLOGY

THE VARIOUS KEY STRATEGIC ISSUES ARE:1.SOURCE OF NEW TECHNOLOGY

2.CHOICE OF NEW TECHNOLOGY

3.TRANSFER & DIFFUSION OF TECHNOLOGY

4.APPLICATION OF TECHNOLOGY

5.TIMING OF INTRODUCTION

TECHNOLOGY LIFE CYCLE

• ALL OBJECTS & SYSTEMS HAVE LIFE CYCLES IN THE FORM OF EMERGECE, GROWING, MATURING & DECLINING.THIS IS TRUE FOR A TECHNOLOGY TOO.

TECHNOLOGICAL FORECASTING• IT USES THE PAST AND PRESENT KNOWLEDGE

TO BUILD THE FUTURE• IT PUTS EMPHASIS ON A SPECIFIC

DEVELOPMENT• IT PROMISES TO SERVE USEFUL FUNCTION• IT PROVIDES USEFUL DATA• IT HELPS TO REDEFINE ITS BUSINESS PROPERLY• IT ENABLES AN ORGANISATION TO AVOID

COSTLY MISTAKES & WASTAGES

BARRIERS IN TECHNOLOGY MANAGEMENT

• LACK OF KNOWLEDGE &TRAINING

• LACK OF LONG RANGE FOCUS

• LACK OF RISK TAKING

INNOVATION MANAGEMENTINNOVATION IS THE PROCESS OF

INTRODUCING NEW WAYS OF DOING THINGS.

“THE ACT OF INTRODUCING SOMETHING NEW OR SOMETHING NEWLY INTRODUCED.”

----THE AMERICAN HERITAGEDICTIONARY

“ANY PRODUCT , SERVICE OR IDEA THAT IS PERCEIVED AS NEW.”

----ROGERS

INNOVATION IN THE NATURE OF NEWNESS

• RADICAL INNOVATION

• SYSTEM INNOVATION

• INCREMENTAL INNOVATION

MANAGEMEENT OF INNOVATION

1.GENERATION OF INNOVATION

A.IDENTIFYING NEED FOR INNOVATION

B.IDEA GENERATION

C.IDEA EVALUATION

D.IDEA SELECTION

2.INNOVATION DIFFUSION

• AWARENESS ABOUT THE INNOVATION OCCURING OUTSIDE THE ORGANISATION

• ASSESSING THE RELEVANCE OF INNOVATION TO THE ORGANISATION

• TRYING THE INNOVATION TO JUDGE ITS FEASIBILITY

• ADOPTION OF THE FEASIBLE INNOVATION

AN EFFICIENT MANAGEMENT OF INNOVATION REQUIRES FOLLOWING TWO ITEMS.

1.LEARNING ORGANISATION

2.KNOLEDGE MANAGEMENT

LEARNING ORGANISATION

THE ORGANISATION WHICH ANTICIPATES LIKELY CHANGES IN THE ENVIRONMENT & GEAR THEIR HUMAN RESOURCES TO FACE THE ENVIRONMENTAL THREATS THAT ARE LIKELY TO BE POSED.SUCH ORGANISATION EMPHASIZES CONTINUOUS ORGANISATIONAL LEARNING AND ARE KNOWN AS LEARNING ORGANISATION.

DEFINITION

GARWIN :“A LEARNING ORGANISATION IS

ONE WHICH IS SKILLED AT CREATING, ACQURING, AND TRANSFERRING KNOWLEDGE & MODIFYING ITS BEHAVIOUR TO REFLECT NEW KNOOWLEDGE & INSIGHTS.”

CHARACTERISTICS• SHARED VISION

• FORMULATION & IMPLEMENTATION OF IDEAS

• COLLABORATION LEARNING

• EMPOWERMENT & LEADERSHIP

• LEARNING CONTINUOUSLY

TYPES

• ADAPTIVE LEARNING

• GENERATIVE LEARNING

DEVELOPING A LEARNING ORGANISATION

• TOP MANAGEMENT COMMITMENT• SHARED VISION• ACCEPTABILITY OF LEARNING• INTRODUCING NEW STRUCTURES,

TECHNIQUES & PROCESS ETC.• REINFORCEMENT/COMMITMENT OF ENTIRE

WORKERS• LEARNING CULTURE

KNOWLEDGE MANAGEMENT

IT IS CREATION, DISTRIBUTION & UTILISATION OF KNOWLEDGE AT THE INDIVIDUAL, GROUP, ORGANISATIONAL & COMMUNIITY LEVELS THROUGH HARNESSING OF PEOPLE,PROCESS& TECHNOLOGY FOR THE BENEFITS OF THOSE INVOLVED & AFFECTED BY IT.

BASIC ELEMENTS

• KNOWLEDGE CREATION

• KNOWLEDGE SHARING

• KNOWLEDGE UTILISATION

SUN PHARMACEUTIAL INDUSTRIES LTD.

• Sun Pharmaceutial industries ltd.(NSE:SUNPHARMA,BSE:524715)is a multinational Pharmaceutial company.

• Its headquarter in Mumbai• It was established by Dilip Shanghvi in 1983• It was listed in stock exchange in1994• It manufactures and sells pharmaceutial formulations and Active

Pharmaceutical Ingredients(API) primarily in India and United states• The company offers formulations in various therapeutic areas, such as

cardiology,psychiatry,neurology,gastroenterology and diabetology. • It also provides APIs such as warfarin, carbamazepine, etodolac, and

clorazepate, as well as anticancers steroids, peptides and controlled substances.

MAJOR ACQUSITIONS• 2014-Ranbaxy laboratories ltd.• 2013-URL Pharma• 2012-Dusa pharmaceuticals• 2011-MSD• 2010-Carco,Taro• 2009-Inwood Laboratories,Inc• 2008-Chattem Chemicals,Inc• 2005-ABLE LABORATORIES

AWARDS

• Mr. Dilip Shanghvi receives Entrepreneur of the Year by Forbes Magazine

• Sun Pharma receives Cardiovascular Pharmaceutical Company of the Year by Forest&Sullivan India Health Care Excellence Awards

• Mr. Dilip Shanghvi receives Business Leader of The Year Award by The Economics Times

• Sun Pharma is listed among The world’s 100 most innovative Companiesby Forbes

• Mr. Dilip Shanghvi receives JRD TATA Corporate Leadership Awardby All India Management Association

R AND D CENRES

New York, USA (Taro) Vadodara, India

Mumbai, India Haifa, Israel (Taro)

Brampton, Canada (Taro) Gurgaon, India

DUSA, USA Cranbury, USA

R & D EXPENDITUREYear 2004-

052005-06

2006-07

2007-08

2008-09

2009-10

2010-11

2011-12

2012-13

2013-14

Total 1427 2015 2787 2859 3320 2242 3313 4449 7042 10418

Revenue 418 481 347 134 222 159 236 362 427 556

Capital 1009 1534 2440 2725 3098 2083 3077 4087 6615 9862

% to revenue

12% 12% 13% 9% 8% 6% 6% 6% 6% 7%

MAN BEHIND THE COMMITMENT

HISTORY AT A GLANCEFOUNDED BY R.C. JUNEJA IN1995 AT A SEED CAPITAL OF 50

LAKHS WITH ONLY 20 EMPLOYEES.

PRODUCTS IN THERAPEUTIC AREA RANGING FROM ANTIBIOTIC & ANTIFUNGALCOMPOUNDS TO GASTROINTESTINAL,CARDIOVASCULAR,DERMAL &ERECTILE DYSFUNCTIONAL MEDICATIONS.

HEAD QUARTER-OKHLA ,NEWDELHI.

REVENUE-3000 CRORES cont…

SUBSIDIARIES- DISCOVERY, LIFESTAR, SPECIAL, VET, FUTURE,MAGNET.

NO. OF EMPLOYEES-10000+

POPULAR PRODUCTS-MOXIKIND-CV, GUDCEF , ALMOKIND-AT ,NUROKIND/PLUS , MANFORCE,PREGANEWS,GAS-O-FAST, ADDICTION DEODRANT

NO. OF COUNTRY OPERATE-15

AWARDS AND RECOGNITIONS• “EMERGING COMPANY OF THE YEAR” AT PHARMA

EXCELLENCY AWARD,2007

• “ENTREPRENEUR OF THE YEAR” BY ERNST AND YOUNG,2011

• “INDIA BUSINESS ICON(PHARMA)AWARD” BYNETWORK 18,2011

• “ACHIEVING BUSINESS EXCELLENCE AWARD” BY CITI COMMERCIAL BANK,2012

MISSION“TO IMPROVE THE QUALITY OF LIFE TO

CONTINUE TO BE RECOGNISED AS A RELIABLE PROVIDER OF HEALTHCARE PRODUCTS AND NURTURE INNOVATION THAT LEADS TO COLLECTIVE EXCELLENCE..”

VISION“TO ENSURE REACH,AFFORDABILITY AND

QUALITY OF OUR PRODUCTS,ACROSS THE COUNTRY FOR A HEALTHIER AND HAPPIER INDIA.”

MANKIND RESEARCH CENTRE• LOCATED IN MANESAR (GURGAON, HARYANA)

• ADMINISTERED BY MORE THAN 200 LEADING SCIENTISTS FROM DIVERSE FIELDS

• 200+ PROJECTS IN PIPELINE

• 5 NEW DRUG DISCOVERY PROJECTS

• RICH HUMAN CAPITAL AND HIGH TECH EQUIPMENT MAKES MANKIND A PIONEER IN THE FIELD OF R&D.

ITS DEVELOPMENT CAPABILITIES INCLUDES:

1.NEW DRUG DISCOVERY AND RESEARCH

• IT FOCUSES ON THE DISCOVERY OF,DEVELOPMENT,RESEARCH AAND COMMERCIALIZATION OF NEW DRUGS THAT ADDRESS DISEASE AREAS WITH SIGNIFICANTLY UNMET MEDICAL NEED.

• EFFORTS DIRECCTED TOWARDS IDENTIFYING AND DEVELOPING NEW THERAPIES FOR DISEASE AREA INCLUDE DIABETES, ARTHRITIS & ANGINA.

2.ACTIVE PHARMACEUTICAL INGREDIENTS

• ADVANTAGE TO CONDUCT COMPLEX REACTIONS WITH PROPER INFRASTRUCTURE

• PRESENTLY IT IS DEVELOPING APIS LIKE ANTIBIOTICS,,ANTIPSHYCHOTIC,ANTIBACTERIAL,ANTIINFLAMMATORY,ANTIASTHMATIC,ANTIALLERGIC,ANTI DIABETES,AND CALCIUM CHANNEL BLOCKERS,DRUGS FOR ARTHRITIS,OSTEOARTHRITIS AND STEROIDS.

3.FORMULATION RESEARCH AND DEVELOPMENT

• OCCUR ACROSS MAJOR THERAPEUTIC AREAS LIKE-GASTRO INTESTINAL AILMENTS, CARDIOVASCULAR DISEASE,PAIN MGMT., ONCOLOGY,PAEDIATRIC-TO DELIVER INTELLECTUAL PROPERTY TO THE ORGANIZATION.

• CURRENTLY IT IS WORKING ON ENHANCING THE BIOAVAILABILITY OF MOLECULES WHICH MAY LEAD TO REDUCTIO IN DOSE & INCREASE THE SAFETY PROFILE OF DRUG.

4.ANALYTICAL R&D• ANALYTICAL R&D INVOLVES PRE-

FORMULATION,STABILITY& DEGRADATION STUDIES ON APIS & OTHER DRUGS,& PREPARATION OF TECHNICAL DOSSIERS FOR REGISTRATION IN INDIA & OTHER COUNTRIES.

• THE ANALYTICAL DEVELOPMENT TEAM PROVIDES SPECIFIC SERVICE TO VARIOUS DEPTTS OF MANKIND RESEARCH CENTRE.

5.INTELLECTUAL PROPERTY MGMT.

• IT HAS AN EXPERIENCED TEAM OF IP PROFESSIONALS SPECIALIZEDIN IP LAWS THAT WORKS DILIGENTLY TO ENSURE THE PROTECTION OF MANKIND’S IP WEALTH.

PRODUCTS(DOMESTIC FORMULATIONS)1.MANKIND PHARMA:• JOURNEY BEGINS IN 1995

• PRODUCT AREA-CARDIOVASCULAR,ANTIBIOTICS,GASTRO INTESTINAL,ANTI-ALLERGIC,ANTI-FUNGAL,NUTRITIONAL ETC.

• SUCCESSFUL PRODUCTS-NORAGYL,RANISPAS,RANIDOMIN,NUROKIND,MOXIKIND,TELMIKIND ETC.

2.DISCOVERY MANKIND• ESTABLISH IN 2002.

• PRODUCT AREA-ANTI-DIABETIC,ANTI-INFECTIVE,GYNAECONOLOGICAL,NUTRITIONALS ,ANTI-ALLERGIC ETC.

• FIRST RANKSED BRANDS-MAHAAAAAFLOX,LIZOFORCE,CANDIFORCE,FYNAL-OZ,MONTICOPE ETC.

3.FUTURE MANKIND

• ESTABLISHED IN 2007

• PRODUCT BASE-SPECIALISE IN MANUFACTURING OF PRODUCTS FOR NEUROPSHYCHIATRY & DENISTRY

• TOP PRODUCTS-CLONAFIT,RANIDOM,FLORA,THERMOKIND, HISTAFREE ETC.

4.SPECIAL MANKIND

• HEAL-O-KIND,• KALOREE 1• GAS-O-FAST• ADDICTION• MANFORCE TABLET• STAY LONG GEL AND ETC.

5.VET MANKIND

• FENDIKIND PLUS BOLUS

• MEGABLOTA SUSPENSION

• BANDYKIND PLUS BOLUS

• NUROKIND-PLUS VET INJECTION

• ENERDYNA LIQUID ETC.

LIFESTAR

• ESTABLISHED IN2005

• PRODUCT BASE-OPTHALMOLOGY,ANTIBIOTICS,ANTI-MALARIA,DERMATOLOGY ETC.

• PRODUCTS BRAND-TERBINAFORCE,OSKAR,ASTHAKIND,VENTIDOX-DL ETC.

MAGNET

• START OPERATION-2007

• PRODUCT BASE- COVERS ALL THERAPEUTIC AREA LIKE NUTRITIONAL,ANTI-BACTERIAL,GASTRO-INTESTENIAL,,PAIN MGMT.,CENTRAL NERVOUS SYSTEM ETC.

• PRODUCT BRANDS-BRUTACEF,NUROKIND FORTE,RACIGYL-SB,RANIDOM-RD,UBINEXT-LC,GUT-OK ETC,

INTERNATIONAL MARKET OPERATION

• NO. OF PRODUCTS-300+

• NO.OF COUNTRIES-15

• REGULATORY AFFAIRS MECHANISM

THANK YOU